We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Curcumin-Encapsulated Nanomicelles Improve Cellular Uptake and Cytotoxicity in Cisplatin-Resistant Human Oral Cancer Cells.
- Authors
Kumbar, Vijay M.; Muddapur, Uday; Bin Muhsinah, Abdullatif; Alshehri, Saad Ali; Alshahrani, Mohammed Merae; Almazni, Ibrahim Abdullah; Kugaji, Manohar S.; Bhat, Kishore; Peram, Malleswara Rao; Mahnashi, Mater H.; Nadaf, Sameer J.; Rooge, Sheetalnath B.; Khan, Aejaz Abdullatif; Shaikh, Ibrahim Ahmed
- Abstract
Oral cancer has a high mortality rate, which is mostly determined by the stage of the disease at the time of admission. Around half of all patients with oral cancer report with advanced illness. Hitherto, chemotherapy is preferred to treat oral cancer, but the emergence of resistance to anti-cancer drugs is likely to occur after a sequence of treatments. Curcumin is renowned for its anticancer potential but its marred water solubility and poor bioavailability limit its use in treating multidrug-resistant cancers. As part of this investigation, we prepared and characterized Curcumin nanomicelles (CUR-NMs) using DSPE-PEG-2000 and evaluated the anticancer properties of cisplatin-resistant cancer cell lines. The prepared CUR-NMs were sphere-shaped and unilamellar in structure, with a size of 32.60 ± 4.2 nm. CUR-NMs exhibited high entrapment efficiency (82.2%), entrapment content (147.96 µg/mL), and a mean zeta potential of −17.5ζ which is considered moderately stable. The cellular uptake and cytotoxicity studies revealed that CUR-NMs had significantly higher cytotoxicity and cellular uptake in cisplatin drug-resistant oral cancer cell lines and parental oral cancer cells compared to plain curcumin (CUR). The DAPI and FACS analysis corroborated a high percentage of apoptotic cells with CUR-NMs (31.14%) compared to neat CUR (19.72%) treatment. Conclusively, CUR-NMs can potentially be used as an alternative carrier system to improve the therapeutic effects of curcumin in the treatment of cisplatin-resistant human oral cancer.
- Subjects
ORAL cancer; CISPLATIN; ANTINEOPLASTIC agents; CANCER cells; DRUG resistance; DRUG resistance in cancer cells; CELL lines; ZETA potential
- Publication
Journal of Functional Biomaterials, 2022, Vol 13, Issue 4, p158
- ISSN
2079-4983
- Publication type
Article
- DOI
10.3390/jfb13040158